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Abstract  
Objective: To estimate the increase in prostate cancer mortality (PCM) and the reduction in 
overtreatment resulting from different Active Surveillance (AS) protocols, compared to treating 
men immediately.   
Subjects and Methods: We use a microsimulation model (MISCAN-Prostate), with natural 
history based on ERSPC data. We estimate probabilities of referral to radical treatment while on 
AS, depending on disease stage, with data from John Hopkins AS cohort. We sample 10 million 
men representative of the US population and we project the effects of applying AS protocols 
differing by time between biopsies, compared to treating men immediately.  
Results: AS with yearly follow-up biopsies for low-risk patients  (≤ T2a-stage and Gleason 6) 
increases the probability of PCM  to 2.6% (1% increase) and reduces overtreatment from 2.5% to 
2.1% (18.4% reduction). With biopsies every three years after the first year, PCM increases by 
2.3% and overtreatment reduces from 2.5% to 1.9% (30.3% reduction). Including intermediate-
risk men  ( > T2a-stage or Gleason 3+4) in AS increases PCM by 2.7% and reduces 
overtreatment from 2.5% to 2.0% (23.1% reduction). These results may not apply to African-
American men. 
Conclusions: Offering AS for low-risk patients is relatively safe. Increasing the biopsy interval 
from yearly to up to every 3 years after the first year, will significantly reduce overtreatment 
among low-risk men, with limited PCM risk.   
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Introduction 
In a time of widespread debate about prostate specific antigen (PSA) screening for prostate 
cancer, Active Surveillance (AS) has emerged as a way to prevent the unnecessary treatment of  
some patients with prostate cancer, or at least, to delay the treatment of the disease [1]. The 
benefit of not treating a patient immediately is the avoidance of the side-effects of radical 
treatment. 
AS consists of the carefully monitoring of men diagnosed with prostate cancer, but not yet 
treated, with PSA tests or repeat biopsies. What still needs to be determined is whether the 
benefits of avoiding side effects outweigh the risk that a patient misses his cure window by not 
treating immediately. 
Currently, there are some AS cohort studies designed to answer this question: Prostate Cancer 
Research International Active Surveillance (PRIAS) [2], UCSF cohort [3], John Hopkins (JH) 
[4] or the Toronto cohort [5] among others [6,7]. However, with the exception of the Toronto 
cohort, their median follow-up times are shorter than 5 years.  In their latest publications, very 
few prostate cancer deaths were reported [2-5,7]. 
Most AS cohorts contain only one AS protocol, usually selecting low-risk patients, with stage 
<T2a and Gleason Score 6 or lower (T2GS6) [6,7]. While in some cohorts follow-up biopsies 
occur yearly (JH [4]), in others biopsy occurs up to every 3 years after the first year (PRIAS [2]).  
It is not yet clear whether AS is safe for intermediate risk patients.  While in the UCSF cohort                
[3]  it was found that the 4-year treatment-free survival (TFS) did not significantly differ 
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between low-risk and intermediate risk men, intermediate risk patients had significantly worse 
outcomes in the Toronto cohort [5].  
Given the multitude of possible avenues for selecting and following men during AS, and the 
limited follow-up data, the use of modeling to evaluate the outcomes of AS protocols is 
necessary. Previously, Xia et al [9] compared immediate radical prostatectomy (RP) and AS for 
low-risk patients in a simulation study and found that AS has a modest effect on  prostate cancer 
mortality (PCM).   
In this article we use a well-validated simulation model (MISCAN) of natural history of prostate 
cancer, that uses JH-AS data to predict TFS, gleason and volume progression. We project the 
lifetime risk of PCM and overtreatment in the situation where AS is given to newly screen-
detected low and intermediate risk men, under different follow-up biopsy intervals, and we 
compare these strategies with treating all men immediately.  
Methods 
Simulation Model 
MISCAN is a microsimulation model, which simulates individual life-histories. A detailed 
description is available in http://cisnet.cancer.gov/prostate/profiles.html and in previously 
published studies [10-13].   
Before detection or death, the model contains 18 health states corresponding to the combination 
of 3 stages (T1, T2 and T3), 3 grades (Gleason less than 7, 7, and more than 7) and whether or 
not cancer is metastasized. Additionally, T2-stage Gleason 6 men are classified as T2a or T2bc 
and Gleason 7 men are classified as 3+4 or 4+3, depending on their remaining lead-time and age 
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group, with their respective proportions based on European Randomized Study of Screening for 
Prostate Cancer (ERSPC)  data. Some natural history parameters were calibrated to ERSPC data 
(durations, transition probabilities, among others), while PSA growth parameters were calibrated 
to jointly to SEER incidence and ERSPC PSA distribution. [13].  
In case the patient is detected outside of screening (“clinically detected”) we assume that he is 
immediately treated. If screen-detected he can either be immediately treated or be assigned to 
AS. 
If immediately treated, we assume an equal chance of being referred to RP or radiation therapy 
(RT). The prostate cancer survival without treatment is assigned at clinical detection and depends 
on stage and grade. It was estimated based on SEER data from the pre-PSA era (1983-1986). In 
order to correct for improvements on the survival not directly associated with screening or 
primary treatment, we add a hazard ratio for prostate cancer survival of 0.82, which was 
calibrated to the observed PCM in the ERSPC control (no screening) group (Supplementary 
Table 1).  
The hazard ratios for prostate cancer survival after radical treatment equal 0.56 for RP based on 
[14] and 0.63 for RT (maintaining the same ratio of benefit between RP and RT from [15]). The 
effect of early detection is applied through an additional probability of cure which decreases 
exponentially with lead-time for non-metastatic cases,  
Cure probability =  1 - exp(cure parameter * lead-time).   
The cure parameter was calibrated to the observed PCM reduction in the ERSPC trial after 11 
years of follow-up and equals -0.22.  (Supplementary Table 1-2, Supplementary Figure 1)  
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Modelling referral to treatment in AS 
A patient in AS may be referred to treatment in four ways: volume progression, gleason upgrade, 
clinical detection and in absence of evidence of biopsy progression. If any of these events occurs 
then we assume that all men are treated.  (Table 1)   
Since the benefit of screening is dependent on lead-time, men who are referred to AS will 
experience a smaller benefit of screening, depending on how much time they are on AS. For 
instance, a patient with a lead-time of 10 years at screen-detection, referred to immediate 
treatment, will have a probability of cure as follows:  1- exp(-0.22 * 10) = 0.89.  That is, there is 
an 89% probability that he is cured, and an 11% probability that he dies from prostate cancer.  If 
the patient would choose AS and be referred to treatment 6 years later, its corresponding cure 
would become,  1- exp(-0.22 * 4) = 0.59.    
TFS is defined as time from screen-detection to radical treatment. We validate TFS projected by 
the model, together with the number of men who experienced volume or gleason upgrade, with 
data from the JH-AS study (Table 2).  We simulated the study 100 times, by selecting patients to 
AS, with approximately the same age distribution and  entrance criteria close to the  JH cohort 
(maximum disease state T1 stage and GS6 and PSA ≤ 10) (Table 2).  
Screening and Active Surveillance Policies 
We sample 10 million men representative of the US age distribution based on US life tables. In 
the basecase, we screen men yearly between 55 and 69, with a PSA threshold for biopsy referral 
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(PSAt) equal to 4, biopsy compliance based on the PLCO trial and every screen-detected man is 
immediately treated.    
We compare the outcomes of treating every man immediately, with admitting low risk patients 
(≤ T2a, Gleason 6, PSA <10) in AS.  We run a set of AS protocols where after the first year, 
biopsy frequency reduces to every 2, 3 or 5 years. We also project the effects of AS, with a 
reduced (biannual) and increased (annual, up to age 74) screening schedule. Assuming that the 
referral rates from AS to radical treatment, for intermediate risk men (≤ T2-stage and 3+4 
Gleason) are similar to those of low risk men, given [7], we also project the effects of admitting 
low and intermediate risk men (≤ T2-stage, 3+4 Gleason) in AS.  (Table 3) 
Outcomes 
The main outcome measures are the lifetime risk of PCM, treatment free life years (TFLY), 
which is the duration from onset of the disease until treatment and the probability of 
overtreatment (defined as the risk that a man is referred to radical treatment, and would not be 
clinically detected in absence of screening, or in other words, an ovediagnosed man who goes 
through radical treatment). Additionally we report the average number of years spent on AS, the 
probability of PCM due to entering AS and the proportion of men in AS left untreated. 
Sensitivity Analyses 
We run the no AS, yearly and every 3-year biopsy protocols, in combination with differential 
screening intensities and referral rates to treatment while in AS. We also examine the effect of no 
efficacy of treatment, and referring men only to either RP or RP (Table 2). Since the model 
parameters are subject to uncertainty, we run a multivariate probabilistic sensitivity analysis 
including, the cure parameter, hazard ratios for treatment and the probabilities of detection in AS 
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(Table 3).  We also examined the assumption of an exponentially decreasing cure benefit, by 
comparing the best fit, with the fit of a linearly decreasing cure benefit. (Supplementary Table 2). 
Results 
Active Surveillance with different entrance and follow-up protocols 
Screening yearly between ages 55 and 69, with a PSAt of 4 (basecase) and treating every man 
immediately results in a lifetime risk of PCM  of 2.6%. This strategy amounts to 7.4 treatment 
free life years (TFLY) per person, which contrasts with 8.7 TFLY per person (17.3% increase) if 
no PSA-based screening is performed and treat every men immediately. However, no screening 
results in a lifetime risk of PCM of 3.3% (Table 5).  
On average, patients who entered AS remained untreated between 5.8 and 9.0 years depending 
on the screening and AS policy. If one refers patients in disease state T2aGS6 to AS then PCM  
increases to 2.6% (1.0% increase), TFLY from 7.4 to 7.7 and overtreatment reduces from 2.5% 
to 2.1% (18% reduction). About 27% of all AS men referred to AS remained untreated and the 
probability of dying due to AS is 1.8%.   
Increasing the biopsy interval after the first year of follow-up from yearly, to two, three or five 
years increases PCM to about 2.6% (respectively, from 1.0% to 1.7%, 2.3% and 3.2% increase), 
and the proportion of men who die from prostate cancer due to AS rises from 1.8% to 3.0%, 
4.1% and 5.9%, respectively. On the other hand, the probability of overtreatment reduces from 
2.1% to 2.0% (25% reduction), 1.9% (30% reduction) and 1.8% (36% reduction). Average years 
spent on AS increases from 5.9 to 9.0.    
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Referring intermediate risk men to AS increases PCM to about 2.6% (2.7% increase), while 
overtreatment decreases from 2.5% to 2.0% (23.1% decrease). The risk of PCM due to AS is 
3.6%. By contrast if we only admit low-risk men and a with biennial biopsies after the first year, 
the risk of PCM due to AS is only 3.0%, but with a higher overdiagnosis reduction              
(25.4% decrease). For univariate and multivariate sensitivity analyses see Supplementary Table 
2-5 and Supplementary Figure 2. 
Active Surveillance with different screening intensities  
In the situation where every men is immediately treated, increasing the stopping age to 74 or 
increasing biopsy compliance lowers the PCM from 2.6% to 2.4% (7.4% and 6.1% decrease, 
respectively). On the other hand, probability of overtreatment increases from 2.5% to 3.9% 
(35.3% increase) or 3.1% (18.5% increase). Introducing AS, with the more intensive screening 
schedule seems to result in a larger effect both on overtreatment reduction and PCM increase 
(Table 5).   
Discussion 
In this study we use a novel approach to model AS, by modelling rates of volume and Gleason 
progression, instead of modelling durations [9] or by using a simplistic assumption of reduced 
treatment benefit for men in AS [17].  
Introducing AS for screen-detected men results, on average, in an interval of between 5.8 and 9.0 
years free of treatment, depending on the AS protocol. If we accept T2aGS6 men in AS with 
yearly biopsies or a biopsy every 3 years after the first year, overtreatment reduces from 2.5% to 
2.1% (18.4% reduction) or 1.9% (30.3% reduction),  PCM remains about 2.6% (1.0% or 2.3% 
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increase), with a probability of dying from prostate cancer due to AS of 1.8% or 4.1%, 
respectively.   
To put these numbers in perspective, in 2014, about 233000 men were expected to be diagnosed 
with prostate cancer in the US [18]. Assuming half of them are screen-detected between ages 55 
and 69 (116500) and that 30% of these men are low-risk and are referred to AS (34950), our 
model predicts that for men with yearly biopsies or a biopsy every three years after the first year,  
either about 9250 or 14250 men will not be overtreated and an extra 625 or 1450 men will die of 
prostate cancer due to entering AS, respectively. 
Our sensitivity analyses showed that these effects will become larger if the intensity of screening 
increases (increased stopping age or higher biopsy compliance), as more screen-detected men are 
classified as low-risk and have a longer lead-time. Admitting intermediate risk men in AS seems 
not to be as efficient as increasing the biopsy interval in AS for low-risk men.  
Our modelling of AS uses a previously validated model of the natural history of prostate cancer 
[10-14], which is mostly based on ERSPC data [19], with US incidence validated to SEER 
[13,14]. By calibrating the sensitivity to Gleason Progression and the probability of detecting 
volume progression given that there is an increase in stage, we are able to match the treatment 
free survival and the number of men experiencing volume and gleason progression during AS to 
observed data in JH AS cohort.  
This has some advantages relative to calibration based only on an AS cohort. First, durations and 
transitions between health states (which in large part determine time on AS) are based on a large 
randomized control trial. Second, the median follow-up of the ERSPC trial is much larger than 
most AS cohorts, which makes our PCM projections potentially more reliable.   
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On the other hand, MISCAN makes some simplifications of the AS protocol compared with the 
current practice in most AS cohorts. The entrance criteria for AS used in MISCAN  include T-
stage, GS and PSA but not the number of positive cores or PSA density. Additionally, there is 
some variability regarding TFS, and number of men experiencing volume and/or gleason 
progression across AS cohorts [6,7].   
The results in this study may not apply to African-American population [20], as the benefit of 
screening is estimated based on an European cohort, and the probabilities of referral to treatment 
while in AS are estimated based on a cohort with very few African-American men [4].  
In contrast, with [9], where AS was modelled as duration from diagnosis to treatment, our 
approach for modelling AS allows one to project the effects of multiple AS strategies, without 
resorting to multiple AS cohort datasets. An additional advantage of this framework is that it 
allows us to jointly model screening and AS strategies. The main disadvantage of this approach 
is that given the difficulty of modelling directly volume progression, we need to make the 
assumption that volume progression can only occur, if there is an increase in T-stage in the 
model.      
Our validation shows that MISCAN is slightly more pessimistic than the observed data in JH 
cohort (2 against 0 observed prostate cancer deaths). Other cohorts showed no PCM at 5 years 
except [21] with 1 prostate cancer death at 3.7 years of follow-up.  This is likely due to the very 
low risk selection of patients in most AS cohorts, which contrasts with the ERSPC population 
used to inform natural history in MISCAN.   
Importantly, we verify that a key statistic, probability of dying due to AS,  which equals 1.8% in 
our model, is in line with previous studies where no benefit of early detection is assumed, and 
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where AS was modelled as duration from diagnosis to treatment (Xia et al [9]: 1.2%) or as an 
assumption about reduced benefit  (Hayes et al [17]: 2%). This rate is also comparable with the 
observed PCM (1.5%) in the Toronto cohort, after 10 years of follow-up [6].  
In this study we did not model quality of life. Heijnsdijk et al [22] finds that introducing quality 
of life adjusted years (QALY’s) reduces the screening benefit by 23%. Delaying treatment with 
AS is a way to mitigate this reduction, due to the avoidance of side-effects. For instance, Hayes 
et al [17] compared AS with several forms of radical treatment and found that AS gives the 
highest expected QALY’s. Using QALY’s will likely favor AS protocols that are less biopsy 
intensive, given the increased risk of biopsy complications [23-25].     
As previously suggested [1-9], our model predicts that AS for low-risk men is relatively safe.  
We project the harms of benefits of several AS strategies and we find that if we increase the 
interval between biopsies after the first year to three years, which is close to the strategy used in 
the PRIAS cohort [2], overtreatment may reduce up to 30%, though with a small increase in 
PCM. These results apply mostly to US population of European ancestry.  
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